Collagen Solutions PLC Hardman & Co: Nearing first proprietary product

TIDMCOS

Collagen Solutions PLC

26 February 2018

Hardman & Co Res: Nearing first proprietary product

Closing in on first proprietary product: Collagen Solutions (COS) is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research and regenerative medicine. A number of investment initiatives have been introduced to accelerate the rate of growth, including global commercial infrastructure and development of a pipeline of finished medical devices, the first of which will be ChondroMimetic for repair of small cartilage lesions. Eight years after implantation, clinical outcomes with ChondroMimetic were at least as good as could be expected, and better than those published in the literature for alternative methods of cartilage repair.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/collagen-solutions-plc-documents/26.02.18-closing-in-on-first-proprietary-product.pdf

 
 To contact us:          Contacts:       mh@hardmanandco.com 
  Hardman & Co            Dr Martin       dmh@hardmanandco.com 
  35 New Broad Street     Hall            gp@hardmanandco.com 
  London                  Dr Dorothea 
  EC2M 1NH                Hill 
  www.hardmanandco.com    Dr Gregoire 
  Follow us on Twitter    Pave 
  @HardmanandCo 
 
                          +44 20 7194 
                          7622

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASEMFWDFASESE

(END) Dow Jones Newswires

February 26, 2018 02:15 ET (07:15 GMT)

Healthcare Inv (LSE:HIO)
過去株価チャート
から 12 2024 まで 1 2025